Revvity, Inc. RVTY announced the receipt of the FDA’s 510(k) clearance for EUROIMMUN’s automated chemiluminescence-based ...

The US Food and Drug Administration (FDA) has cleared Revvity’s automated chemiluminescence-based immunoassay (ChLIA) test for free testosterone. The authorisation by the agency marks the first ...

The clinical chemistry test is intended to help diagnose heart failure using the N-terminal pro b-type natriuretic peptide biomarker.

These chemiluminescent, no-wash assays are ideally ... advantageously with conventional enzyme-linked immunosorbent assay (ELISA). ELISA is the most widely used detection platform for the ...

The ABBOTT PRISM System is an automated immunoassay analyzer designed to perform Chemiluminescent immunoassay (ChLIA) technology. The ABBOTT PRISM performs batch/continuous access and STAT ...

Anbio Biotechnology ("Anbio"), a global leader in in-vitro diagnostic technologies, is excited to announce its participation ...

(RTTNews) - Revvity (RVTY) received 510(k) clearance from FDA for EUROIMMUN's automated chemiluminescence-based immunoassay test for free testosterone. The company noted that this is the only FDA ...

Comprehensive Assay Portfolio: Beyond traditional chemiluminescence applications, it supports advanced diagnostics for specialized conditions such as stroke, Alzheimer's disease, thrombosis, and ...

The ADVIA Centaur ® XPT Immunoassay System is engineered for ... testing with advanced acridinium ester technology—evolving chemiluminescence that provides the flexibility to meet changing ...